SLXN underwent a significant business combination in August 2024 that dramatically improved its financial position, with cash increasing over 400% and the company moving from negative to positive stockholders' equity.
The business combination with Moringa Acquisition Corp appears to have been a reverse merger/SPAC transaction that provided substantial capital infusion and public market access. However, the company remains pre-revenue with increasing R&D spending and deteriorating operating cash flow, indicating continued cash burn despite the improved balance sheet position.
SLXN's financials show a dramatic transformation driven by the business combination, with cash and equivalents surging 405% to $6.0M and stockholders' equity flipping from -$4.0M to +$2.6M as total liabilities decreased 33%. Despite this capital infusion, operational metrics deteriorated with R&D expenses growing 23% to $7.1M and operating cash flow burning faster at -$10.8M versus -$8.4M previously. The improved balance sheet provides runway, but accelerating cash burn and pre-revenue status signal continued dilution risk for investors.
Net interest income grew 453.6% — benefiting from rate environment or loan book expansion.
Cash position surged 404.7% — strong cash generation or capital raise providing significant financial cushion.
Current assets grew 195% — improving short-term liquidity or inventory/receivables build.
Equity base grew 165.3% — retained earnings accumulation or equity issuance strengthening the balance sheet.
Asset base grew 152% — expansion through organic growth, acquisitions, or capital deployment.
Capex reduced 59.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.
Liabilities reduced 32.7% — deleveraging improves balance sheet strength and financial flexibility.
Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.
Net income grew 27.9% — bottom-line growth signals improving overall business health.
R&D investment increased 22.8% — signals commitment to future product development, though near-term margin impact.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →